Keep in mind that the company has to play nice with the FDA until they exhaust all avenues through negotiations. For one thing, the FDA could give them the green light for all trig levels not on statin therapy. While they play the FDA game shareholders can take them to the wall. Heck, as taxpayers we should take them to the wall, they are killing US drug innovation and increasing the cost of new drugs.
News 
Market Data 
Discover 
